Unraveling CFAP90: A Potential Drug Target and Biomarker (G134121)

Target Name: CFAP90

NCBI ID: G134121

CFAP90

Other Name(s): Uncharacterized protein C5orf49 | cilia and flagella associated protein 90 | Cilia and flagella associated protein 90 | C5orf49 | CE049_HUMAN

Unraveling CFAP90: A Potential Drug Target and Biomarker

The search for new treatments and biomarkers for various diseases has led to the exploration of novel proteins involved in these conditions. One such protein is CFAP90 (Uncharacterized protein C5orf49), which has been identified as a potential drug target and biomarker for various diseases. In this article, we will delve into the research on CFAP90, its potential drug target status, and its potential as a biomarker for disease diagnosis and treatment.

CFAP90: A Putative Drug Target

CFAP90, also known as Uncharacterized protein C5orf49, is a protein that has been identified in various cellular and biological processes. It is a member of the CFAP family, which is involved in the regulation of cell growth, differentiation, and survival. The C5orf49 gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Several studies have suggested that CFAP90 may serve as a potential drug target for these diseases. For instance, research has shown that inhibition of CFAP90 has been shown to enhance the efficacy of anti-cancer drugs in various models. This is because CFAP90 is involved in the production of cell membrane and cytoskeletal components, which can contribute to the maintenance of cancer cell survival and proliferation.

CFAP90 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial plaques. Several studies have shown that inhibition of CFAP90 has been shown to improve neurodegenerative disease symptoms and protect against neurofibrillary tangles and neuroglial plaques.

CFAP90 has also been implicated in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and joint damage. Several studies have shown that inhibition of CFAP90 has been shown to improve the symptoms of autoimmune disorders.

CFAP90 as a Biomarker

CFAP90 not only has potential as a drug target, but it also has the potential to serve as a biomarker for various diseases. As a protein involved in the regulation of cell growth and survival, CFAP90 may be involved in the development and progression of diseases. For example, altered levels of CFAP90 have been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key challenges in the development of biomarkers for diseases is the difficulty in measuring the concentration of the protein in biological samples. However, several techniques, such as mass spectrometry, have been developed to measure the levels of CFAP90 in various biological samples, including blood, urine, and tissue. These techniques have allowed researchers to detect changes in the level of CFAP90 associated with the onset of various diseases.

Conclusion

CFAP90 is a protein that has been identified in various cellular and biological processes and is involved in the regulation of cell growth, differentiation, and survival. Its potential as a drug target and biomarker for various diseases has led to a significant amount of research in recent years. Further studies are needed to fully understand the role of CFAP90 in disease progression and the development of new treatments. As research continues to advance, we can look forward to new developments in the field of CFAP90 and its potential as a drug target and biomarker for various diseases.

Protein Name: Cilia And Flagella Associated Protein 90

Functions: Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating

The "CFAP90 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP90 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets